
Understanding 8q24.3 Microdeletion Syndrome: The Role of Genetic Testing
Deletion at 8q24.3 is linked with intellectual disability and developmental delay, and exome sequencing flagged de novo variants in the PUF60 and NAA15 genes.

MD · MBA
Physician specializing in genetic analysis and personalized preventive medicine, and author of Outsmart Your Genes.
Brandon Colby is a physician-expert in the fields of genetic analysis and Personalized Preventive Medicine. He holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University's Graduate School of Business, and a degree in Genetics from the University of Michigan.
Dr. Colby is the author of the book Outsmart Your Genes and has developed numerous technologies that improve the analysis, interpretation, and actionability of genome sequencing data. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).
Articles by Brandon Colby, MD are reviewed for accuracy by Sequencing's medical and scientific team. This page is for informational purposes and does not constitute medical advice.

Deletion at 8q24.3 is linked with intellectual disability and developmental delay, and exome sequencing flagged de novo variants in the PUF60 and NAA15 genes.

Mutations in the ADNP gene bring together intellectual disability, autism spectrum disorder and congenital anomalies; testing supports early intervention.

The rs10033900 variant near the complement factor I gene has been tied to AMD14 risk in the Han Chinese population, informing monitoring and genetic counseling.

Central vision loss from ARMD15 affects reading and recognizing faces; genetic markers can flag higher risk and guide closer monitoring and dietary changes.

Intellectual disability, obstructive sleep apnea, developmental delay and mild dysmorphic features overlap with other disorders, so AHDC1 testing settles the diagnosis.

IFIH1 mutations drive the immune activation behind AGS7, which shows up in infancy or early childhood with developmental delay, neurological issues and skin changes.

No tear production, swallowing difficulty and intellectual disability set this syndrome apart from Triple A syndrome, and DNA testing pinpoints the mutation involved.

Excess aldosterone raises blood pressure and can rarely come with seizures; KCNJ5, CACNA1D and ATP1A1 mutations separate hereditary from sporadic cases.